Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;62(9):12296-12306.
doi: 10.1007/s12035-025-05057-3. Epub 2025 May 19.

S100B Mitigates Cytoskeletal and Mitochondrial Alterations in a Glial Cell Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Affiliations

S100B Mitigates Cytoskeletal and Mitochondrial Alterations in a Glial Cell Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Ana Sofia Boasinha et al. Mol Neurobiol. 2025 Sep.

Abstract

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurological disorder caused by mutations in the SACS gene, resulting in the loss of sacsin function. Sacsin is a multidomain protein that plays key roles in chaperone regulation, protein quality control, and neurofilament dynamics. Sacsin deficiency leads to disruption of intermediate filament and mitochondrial networks. S100B, a multifunctional brain-enriched protein, exhibits protective neuroprotective functions that include chaperone activity and interactions with filament proteins and mitochondria. In this study, we used an established astroglial C6 cell model of ARSACS to investigate the potential compensatory effects of S100B on sacsin loss with respect to neurofilament integrity and mitochondrial morphological and functional hallmarks. Our results demonstrate that sacsin deletion induces S100B upregulation at both mRNA and protein levels, with the S100B protein colocalizing with perinuclear nestin aggregates and filamentous mitochondria networks. Genetic silencing and pharmacological inhibition of S100B exacerbate filament protein aggregation and mitochondrial defects, while supplementation with exogenous recombinant S100B improves ARSACS hallmarks, including decreased nestin aggregates. These findings provide evidence for functional compensation of sacsin loss by S100B in glial cells, and suggests a potential role for glial cells in ARSACS.

Keywords: ARSACS; Astroglia; Intermediate filaments; Mitochondria; Molecular chaperones; S100B; Sacsin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Sacsin deletion increases S100B levels and alters its subcellular distribution. a Representative images of C6 and C6Sacs−/− cells showing nestin juxtanuclear accumulation (green), nucleus (blue) and mitochondria (magenta). Scale bar – 20 µm. b, c Quantitative analysis of nestin area and nestin tangles circularity, respectively. Data were collected from 6 independent experiments with a total number of 982 WT cells and 1449 KO cells analysed. Data are shown as mean ± SEM; unpaired student’s t-test: *P < 0.05, **P < 0.01, ****P < 0.0001. d, e Quantitative analysis of mitochondria aspect ratio (d) and total branch length per area (µm) (e), respectively. Data were collected from 8 independent experiments with a total number of 481 WT cells and 631 KO cells analysed. Data are shown as mean ± SEM; unpaired student’s t-test: *P < 0.05, **P < 0.01, ****P < 0.0001. f Representative western blots showing sacsin deletion and S100B overexpression levels in C6 and C6Sacs−/−cells. g Levels of S100B mRNA are upregulated in C6Sacs−/− (n = 6, p-value = 0.0183). Data are expressed as fold change over S100B levels in reference C6 cells. Data are represented as mean values ± SEM and statistical analysis was performed through Student’s t-test. *p < 0.05. h, i Representative images of C6 and C6Sacs−/− cells with endogenous S100B (h) and overexpression of an exogenous S100B-cerulean construct (i), respectively. When overexpressed in the C6Sacs−/−cells, S100B locates between IFs tangles and nucleus in C6Sacs−/−cells, indicated by white arrow. Scale bar – 20 µm
Fig. 2
Fig. 2
Effects of S100B modulation on nestin accumulation and mitochondrial morphology in C6Sacs−/− cells. a Immunocytochemistry images showing nestin distribution (green), mitochondrial network (magenta) and nucleus (blue) after transfection with siRNA control or against S100B; after 48 h incubation with pentamidine (0.5 µM) and after incubation with exogenous S100B (30 µM). Scale bar – 20 µm. b Representative western blot showing inhibition of S100B with siRNA and decrease in nestin levels of expression. c Densitometric analysis of western blots normalized to GAPDH levels. Fold-change representation of S100B and Nestin comparing to C6Sacs−/− cells transfected with siRNA control (p-values = 0.0010 and 0.0284, respectively; unpaired t-test, n = 5). d Graphical representation of the percentage of cells with nestin accumulation. Data are shown as mean ± SEM; unpaired student’s t-test: *P < 0.05, **P < 0.01. e, f Quantitative analysis of nestin area (µm2) and nestin tangle circularity, respectively, following S100B inhibition with siRNA (752 cells) or 0.5 µM pentamidine (1422 cells) or exposure to 30 µM of exogenous S100B (1055 cells). siRNA control (628 cells) was used for comparison with siRNA S100B and non-treated C6Sacs−/− cells (2117 cells) were used as control for pentamidine and exogenous S100B. Data were obtained from at least 3 independent experiments and are shown as mean ± SEM; one-way ANOVA followed by Tukey’s test: *P < 0.05, **P < 0.01, ****P < 0.0001. g, h Quantitative analysis of mitochondria aspect ratio and total branch length per area (1/µm), respectively following S100B inhibition with siRNA (736 cells) or 0.5 µM pentamidine (428 cells) or exposure to 30 µM of exogenous S100B (398 cells). siRNA control (498 cells) was used for comparison with siRNA S100B and non-treated C6Sacs−/− cells (636 cells) were used as control for pentamidine and exogenous S100B. Data were collected from at least 3 independent experiments. Data are shown as mean ± SEM; one-way ANOVA followed by Tukey’s test: *P < 0.05, **P < 0.01, ****P < 0.0001
Fig. 3
Fig. 3
Pharmacological inhibition of S100B activity influences mitochondrial homeostasis and function. a Number of mitochondria per cell comparing C6 (483 cells), C6Sacs−/− (636 cells) and C6Sacs−/− treated with pentamidine (428 cells). Data are shown as mean ± SEM; one-way ANOVA followed by Tukey’s test: ****P < 0.0001. b-f Transcript levels of DRP1, MFN2, OPA1, TFAM and LDH in C6 and C6Sacs−/− incubated with pentamidine or the vehicle (DMSO 0.1% v/v). Data are represented as mean ± SEM (n = 4–10 independent experiments), normalized versus reference C6 cells. Statistical analysis was performed through one-way ANOVA followed by Tukey’s test: *P < 0.05. g LDH activity in the same experimental groups. Data are represented as mean ± SEM of 7 independent experiments, normalized versus reference C6 cells. h ATP levels are represented as mean ± SEM of 5 independent experiments, normalized versus reference C6 cells. Statistical analysis was performed through one-way ANOVA followed by Tukey’s test:****p < 0.0001. i Graphical representation of ratio between JC-1 aggregates (FL2—585/42 nm) and JC-1 monomers (FL1—530/30 nm). Data are represented as mean ± SEM (n = 4 independent experiments), Statistical analysis was performed through one-way ANOVA followed by Tukey’s test:*p < 0.05

Similar articles

References

    1. Salem IH, Blais M, Zuluaga-Sánchez VM et al (2025) ARSACS: clinical features, pathophysiology and iPS-derived models. Cerebellum 24(1):24. 10.1007/s12311-024-01777-9 - PubMed
    1. Synofzik M, Soehn AS, Gburek-Augustat J et al (2013) Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): Expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis 8. 10.1186/1750-1172-8-41 - PMC - PubMed
    1. Engert J, Bérubé P, Mercier J, et al (2000) ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 24:120–125. 10.1038/72769 - PubMed
    1. Aly KA, Moutaoufik MT, Zilocchi M et al (2022) Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)☆. Curr Opin Chem Biol 71:102211. 10.1016/j.cbpa.2022.102211 - PubMed
    1. Parfitt DA, Michael GJ, Vermeulen EGM et al (2009) The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1. Hum Mol Genet 18:1556–1565. 10.1093/hmg/ddp067 - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources